The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts

Michael J. Silverberg, Linda Ahdieh, Alvaro Muñoz, Kathryn Anastos, Robert D. Burk, Susan Cu-Uvin, Ann Duerr, Ruth M. Greenblatt, Robert S. Klein, Stewart Massad, Howard Minkoff, Laila Muderspach, Joel Palefsky, Eva Piessens, Paula Schuman, Heather Watts, Keerti V. Shah

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: HIV infection and associated immunodeficiency are known to alter the course of human papillomavirus (HPV) infections and of associated diseases. Goal: This study investigated the association between HIV and HPV and genital warts. Study Design: HPV testing and physical examinations were performed in two large prospective studies: the Women's Interagency HIV Study (WIHS) and the HIV Epidemiology Research Study (HERS). Statistical methods incorporating dependencies of longitudinal data were used to examine the relationship between HIV and HPV and genital warts. Results: A total of 1008 HIV-seronegative and 2930 HIV-seropositive women were enrolled in the two studies. The prevalence of HPV 6 or 11 was 5.6 times higher in HIV-seropositive women in the WIHS and 3.6 times higher in the HERS. Genital wart prevalence increased by a factor of 3.2 in the WIHS and 2.7 in the HERS in HIV-seropositive women. In the WIHS, infection with HPV type 6 or 11, in comparison with no HPV infection, was associated with odds of genital wart prevalence of 5.1 (95% CI: 2.9-8.8), 8.8 (95% CI: 6.1-12.8), and 12.8 (95% CI: 8.8-18.8) in HIV-seronegative women, HIV-seropositive women with ≥201 CD4 cells/μl, and HIV-seropositive women with ≥200 CD4 cells/μl, respectively. In the HERS, infection with HPV type 6 or 11 was associated with odds of 2.7 (95% CI: 1.6-4.6), 4.9 (95% CI: 3.2-7.7), and 5.3 (95% CI: 3.3-8.5) in these same groups. Other HPV types showed a similar dose-response relation, but of substantially lower magnitude and statistical significance. Conclusions: HIV infection and immunodeficiency synergistically modified the relation between HPV 6 or 11 infection and genital wart prevalence.

Original languageEnglish (US)
Pages (from-to)427-435
Number of pages9
JournalSexually Transmitted Diseases
Volume29
Issue number8
StatePublished - 2002
Externally publishedYes

Fingerprint

Human papillomavirus 11
Human papillomavirus 6
Condylomata Acuminata
HIV Infections
HIV
Infection
Epidemiology
Papillomavirus Infections
Research

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)

Cite this

The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. / Silverberg, Michael J.; Ahdieh, Linda; Muñoz, Alvaro; Anastos, Kathryn; Burk, Robert D.; Cu-Uvin, Susan; Duerr, Ann; Greenblatt, Ruth M.; Klein, Robert S.; Massad, Stewart; Minkoff, Howard; Muderspach, Laila; Palefsky, Joel; Piessens, Eva; Schuman, Paula; Watts, Heather; Shah, Keerti V.

In: Sexually Transmitted Diseases, Vol. 29, No. 8, 2002, p. 427-435.

Research output: Contribution to journalArticle

Silverberg, MJ, Ahdieh, L, Muñoz, A, Anastos, K, Burk, RD, Cu-Uvin, S, Duerr, A, Greenblatt, RM, Klein, RS, Massad, S, Minkoff, H, Muderspach, L, Palefsky, J, Piessens, E, Schuman, P, Watts, H & Shah, KV 2002, 'The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts', Sexually Transmitted Diseases, vol. 29, no. 8, pp. 427-435.
Silverberg, Michael J. ; Ahdieh, Linda ; Muñoz, Alvaro ; Anastos, Kathryn ; Burk, Robert D. ; Cu-Uvin, Susan ; Duerr, Ann ; Greenblatt, Ruth M. ; Klein, Robert S. ; Massad, Stewart ; Minkoff, Howard ; Muderspach, Laila ; Palefsky, Joel ; Piessens, Eva ; Schuman, Paula ; Watts, Heather ; Shah, Keerti V. / The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. In: Sexually Transmitted Diseases. 2002 ; Vol. 29, No. 8. pp. 427-435.
@article{6d089acb7caa49aaaa40298642a8d15b,
title = "The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts",
abstract = "Background: HIV infection and associated immunodeficiency are known to alter the course of human papillomavirus (HPV) infections and of associated diseases. Goal: This study investigated the association between HIV and HPV and genital warts. Study Design: HPV testing and physical examinations were performed in two large prospective studies: the Women's Interagency HIV Study (WIHS) and the HIV Epidemiology Research Study (HERS). Statistical methods incorporating dependencies of longitudinal data were used to examine the relationship between HIV and HPV and genital warts. Results: A total of 1008 HIV-seronegative and 2930 HIV-seropositive women were enrolled in the two studies. The prevalence of HPV 6 or 11 was 5.6 times higher in HIV-seropositive women in the WIHS and 3.6 times higher in the HERS. Genital wart prevalence increased by a factor of 3.2 in the WIHS and 2.7 in the HERS in HIV-seropositive women. In the WIHS, infection with HPV type 6 or 11, in comparison with no HPV infection, was associated with odds of genital wart prevalence of 5.1 (95{\%} CI: 2.9-8.8), 8.8 (95{\%} CI: 6.1-12.8), and 12.8 (95{\%} CI: 8.8-18.8) in HIV-seronegative women, HIV-seropositive women with ≥201 CD4 cells/μl, and HIV-seropositive women with ≥200 CD4 cells/μl, respectively. In the HERS, infection with HPV type 6 or 11 was associated with odds of 2.7 (95{\%} CI: 1.6-4.6), 4.9 (95{\%} CI: 3.2-7.7), and 5.3 (95{\%} CI: 3.3-8.5) in these same groups. Other HPV types showed a similar dose-response relation, but of substantially lower magnitude and statistical significance. Conclusions: HIV infection and immunodeficiency synergistically modified the relation between HPV 6 or 11 infection and genital wart prevalence.",
author = "Silverberg, {Michael J.} and Linda Ahdieh and Alvaro Mu{\~n}oz and Kathryn Anastos and Burk, {Robert D.} and Susan Cu-Uvin and Ann Duerr and Greenblatt, {Ruth M.} and Klein, {Robert S.} and Stewart Massad and Howard Minkoff and Laila Muderspach and Joel Palefsky and Eva Piessens and Paula Schuman and Heather Watts and Shah, {Keerti V.}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "427--435",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts

AU - Silverberg, Michael J.

AU - Ahdieh, Linda

AU - Muñoz, Alvaro

AU - Anastos, Kathryn

AU - Burk, Robert D.

AU - Cu-Uvin, Susan

AU - Duerr, Ann

AU - Greenblatt, Ruth M.

AU - Klein, Robert S.

AU - Massad, Stewart

AU - Minkoff, Howard

AU - Muderspach, Laila

AU - Palefsky, Joel

AU - Piessens, Eva

AU - Schuman, Paula

AU - Watts, Heather

AU - Shah, Keerti V.

PY - 2002

Y1 - 2002

N2 - Background: HIV infection and associated immunodeficiency are known to alter the course of human papillomavirus (HPV) infections and of associated diseases. Goal: This study investigated the association between HIV and HPV and genital warts. Study Design: HPV testing and physical examinations were performed in two large prospective studies: the Women's Interagency HIV Study (WIHS) and the HIV Epidemiology Research Study (HERS). Statistical methods incorporating dependencies of longitudinal data were used to examine the relationship between HIV and HPV and genital warts. Results: A total of 1008 HIV-seronegative and 2930 HIV-seropositive women were enrolled in the two studies. The prevalence of HPV 6 or 11 was 5.6 times higher in HIV-seropositive women in the WIHS and 3.6 times higher in the HERS. Genital wart prevalence increased by a factor of 3.2 in the WIHS and 2.7 in the HERS in HIV-seropositive women. In the WIHS, infection with HPV type 6 or 11, in comparison with no HPV infection, was associated with odds of genital wart prevalence of 5.1 (95% CI: 2.9-8.8), 8.8 (95% CI: 6.1-12.8), and 12.8 (95% CI: 8.8-18.8) in HIV-seronegative women, HIV-seropositive women with ≥201 CD4 cells/μl, and HIV-seropositive women with ≥200 CD4 cells/μl, respectively. In the HERS, infection with HPV type 6 or 11 was associated with odds of 2.7 (95% CI: 1.6-4.6), 4.9 (95% CI: 3.2-7.7), and 5.3 (95% CI: 3.3-8.5) in these same groups. Other HPV types showed a similar dose-response relation, but of substantially lower magnitude and statistical significance. Conclusions: HIV infection and immunodeficiency synergistically modified the relation between HPV 6 or 11 infection and genital wart prevalence.

AB - Background: HIV infection and associated immunodeficiency are known to alter the course of human papillomavirus (HPV) infections and of associated diseases. Goal: This study investigated the association between HIV and HPV and genital warts. Study Design: HPV testing and physical examinations were performed in two large prospective studies: the Women's Interagency HIV Study (WIHS) and the HIV Epidemiology Research Study (HERS). Statistical methods incorporating dependencies of longitudinal data were used to examine the relationship between HIV and HPV and genital warts. Results: A total of 1008 HIV-seronegative and 2930 HIV-seropositive women were enrolled in the two studies. The prevalence of HPV 6 or 11 was 5.6 times higher in HIV-seropositive women in the WIHS and 3.6 times higher in the HERS. Genital wart prevalence increased by a factor of 3.2 in the WIHS and 2.7 in the HERS in HIV-seropositive women. In the WIHS, infection with HPV type 6 or 11, in comparison with no HPV infection, was associated with odds of genital wart prevalence of 5.1 (95% CI: 2.9-8.8), 8.8 (95% CI: 6.1-12.8), and 12.8 (95% CI: 8.8-18.8) in HIV-seronegative women, HIV-seropositive women with ≥201 CD4 cells/μl, and HIV-seropositive women with ≥200 CD4 cells/μl, respectively. In the HERS, infection with HPV type 6 or 11 was associated with odds of 2.7 (95% CI: 1.6-4.6), 4.9 (95% CI: 3.2-7.7), and 5.3 (95% CI: 3.3-8.5) in these same groups. Other HPV types showed a similar dose-response relation, but of substantially lower magnitude and statistical significance. Conclusions: HIV infection and immunodeficiency synergistically modified the relation between HPV 6 or 11 infection and genital wart prevalence.

UR - http://www.scopus.com/inward/record.url?scp=0036323455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036323455&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 427

EP - 435

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 8

ER -